Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease

American Journal of Cardiology

Volumn 83, Issue 10, 1999, Pages 1490-1494

  Glueck, Charles J ^a   Lang, James E ^a   Tracy, Trent ^a   Sieve Smith, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CEREBROVASCULAR ACCIDENT; CLAUDICATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RISK FACTOR; SMOKING; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

AGED; ANTIBODIES, ANTICARDIOLIPIN; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 0033562874     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00130-7     Document Type: Article

References (20)

1. Hughes J.R., Davies J.A. Anticardiolipin antibodies in clinical situations associated with a risk of thrombotic events. Thromb Res. 89:1998;101-106.
2. Vaarala O., Manttari M., Manninen V., Tenkanen L., Purrunen M., Aho K., Palosuo T. Anti-cardiolipin antibodies and risk of MI in a prospective cohort of middle-aged men. Circulation. 91:1995;23-27.
3. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., Lefvert A.K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict MI. Arterioscler Thromb Vasc Biol. 17:1997;3159-3163.
4. Zukerman E., Toubi E., Shiran A., Sabo E., Shmuel Z., Golan T.D., Abinader E., Yeshurun D. Anticardiolipin antibodies and acute MI in non-systemic lupus erythematosus patients a controlled study . Am J Med. 101:1996;381-386.
5. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., Alam Z., Carey J.L. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 28:1997;1660-1665.
6. Munts A.G., van Genderen P.J., Dippel P.W., van Kooten F, Koudstaal P.J. Coagulation disorders in young adults with acute cerebral ischemia. J Neurol. 245:1998;21-25.
7. Kristensen B., Malm J., Carlberg R., Stegmayr B., Backman C., Fagerlund M., Olsson T. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke. 28:1997;1702-1709.
8. Nityanand S., Bergmark C., de Faire U., Swedenborg J., Holm G., Lefvert A.K. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med. 238:1995;437-443.
9. Nielson T.G., Nordesgaard B.G., von Jessen F., Andreasen J.J., Wiik A., Hecgaard N.H., Schroeder T.V. Antibodies of cardiolipin may increase the risk of failure of peripheral vein bypasses. Eur J Vasc Endovasc Surg. 14:1997;177-184.
10. Ludia C., Domenico P., Monia C., Emilia A., Sandra F., Agatina A.L., Massimo M., Cristina G., Piero D.R., Ignazio S., Rosanna A., Franco G.G. Antiphospholipid antibodies a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity. 27:1998;141-148.
11. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am. 81:1997;151-177.
12. Moll S., Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 127:1997;177-185.
13. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 332:1995;993-997.
14. Glueck C.J., Lang J.E. Lipoprotein Metabolism in the Elderly. Abrams W.B., Beers M.H., Berkow R.B. The Merck Manual of Geriatrics. 1995;1023-1052 Merck and Co, Rahway, NJ.
15. Gruppo R., Glueck C.J., McMahon R.E., Bouquot J., Becker A., Tracy T., Wang P. Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Pathophysiology of osteonecrosis of the jaw. J Lab Clin Med. 127:1996;481-489.
16. Glueck C.J., Shaw P., Lang J., Tracy T., Sieve-Smith L., Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiology. 75:1995;132-136.
17. Glueck C.J., Glueck H.I., Tracy T., Speirs J., McCray C., Stroop D. Relationship between Lp(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators. Metabolism. 42:1993;236-246.
18. Snedecor B.W., Cochran W.G. Statistical Methods. 7th ed. 1980;State University Press, Ames, IA.
19. Horkko S., Miller E., Dudl E., Reaven P., Curtiss L.K., Zvaifler N.J., Terkeltaub R., Pierangeli S.S., Branch D.W., Palinski W., Witztum J.L. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 98:1996;815-825.
20. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204-210.